NCT05180422 2023-10-18
A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis
Criterium, Inc.
Phase 1/2 Withdrawn
Criterium, Inc.
Hoosier Cancer Research Network